A committee of outside clinical trial observers has recommended that Praxis Precision Medicines stop testing its experimental treatment for essential tremor after an interim analysis of one study ...
Praxis Precision Medicines has reported a 56.3% median reduction in seizure frequency from baseline in a midphase trial, encouraging the biotech to push ahead with phase 2/3 plans despite almost a ...
On Tuesday, Praxis Precision Medicines Inc. (NASDAQ:PRAX) released topline results for its EMBOLD Phase 2 proof-of-concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic ...
BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines (PRAX), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results